-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 10, the latest announcement on the official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of the People's Republic of China announced that the zolbetuximab for injection declared by Astellas has obtained an implied license for a clinical trial in China, and the indication is metastatic pancreas.
Screenshot source: CDE official website
Claudins proteins are tight junction molecules
Although Claudin 18.
In China, zolbetuximab was first approved for clinical use in 2018 for the indication of locally advanced unresectable or metastatic, Claudin18.
The ClinicalTrials.
It is hoped that the follow-up clinical study of zolbetuximab will proceed smoothly and bring new treatment options to patients as soon as possible
References:
[1] The official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China.